Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
Tumor-Infiltrating lymphocyte grade IDs melanoma survival
Tumor-infiltrating lymphocyte grade is an independent predictor of melanoma-specific survival and sentinel lymph node status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

To investigate whether the density and distribution of TILs independently predicts SLN status and survival, Farhad Azimi, of the Melanoma Institute Australia in Sydney, and colleagues reviewed data from 1,865 patients with a single localized primary cutaneous melanoma ≥0.75 mm in thickness.

The researchers observed an inverse association between TIL grade and tumor thickness, mitotic rate, and Clark level. Sixty-one percent of patients underwent a SLN biopsy and 22.1 percent were positive. SLN positivity decreased with increasing TIL grade, ranging from 27.8 percent for TIL grade 0 to 5.6 percent for TIL grade 3 (P < 0.001). Decreasing age, decreasing TIL grade, ulceration, increasing tumor thickness, satellitosis, and increasing mitoses were significant predictors of SLN positivity. Independent predictors of melanoma-specific survival were tumor thickness, ulceration, satellitosis, mitotic rate, TIL grade, and sex. Survival was 100 percent in those with TIL grade 3.

"Ultimately, a greater understanding of the mechanisms controlling TILs in melanoma may provide avenues for developing important new immunotherapeutic strategies for patients with ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Women have clear melanoma survival advantage over men

May 1, 2012

(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012

(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Lymphomas tied to metabolic disruption

July 17, 2015

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.